Successful use of streptokinase for the treatment of empyema thoracis during advanced pregnancy: A case report  by Nir, Samuel et al.
Respiratory Medicine CME (2009) 2, 21e24CASE REPORT
Successful use of streptokinase for the treatment of
empyema thoracis during advanced pregnancy:
A case reportSamuel Nir a, Lalazar Gadi a,*, Shuvy Mony a, Mizrahi Meir a,
Granados Jaime a, Elami Amir c, Izhar Uzi c, Liebowitz Gil a,
Ilan Yaron a, Berkman Neville a,ba Department of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel
b Institute of Pulmonology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
c Department of Cardiothoracic surgery, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Received 5 September 2008; accepted 15 October 2008KEYWORDS
Streptokinase;
Empyema;
PregnancyAbbreviations: VATS, Video assisted t
American college of chest physicians.
* Correspondence to: Gadi Lalazar M
Hadassah Hebrew University Medica




1755-0017/$34 ª 2008 Elsevier Ltd. A
doi:10.1016/j.rmedc.2008.10.004Summary
Pneumonia complicates as many as 2.7 in every 1000 pregnancies putting both mother and fetus
at increased risk. Parapneumonic pleural effusion is generally managed by thoracocentesis and,
if ‘‘complicated’’, by tube thoracostomy. If conservative management is unsuccessful, surgical
decortication may be necessary. We report the case of a 24 year old gravida, who at 33 weeks
of gestation presented to the emergency department with right sided pneumonia complicated
by empyema. Blood and pleural fluid cultures were positive for Streptococcus pneumonia. Treat-
ment with antibiotics, tube thoracsotomy and interpleural streptokinase led to resolution of the
pneumonia and empyema without the need for surgical intervention. The patient carried her
pregnancy to term and delivered a healthy baby after 39 weeks and 5 days of gestation. To our
knowledge this is the first report of empyema treated with streptokinase in advanced pregnancy.
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Pneumonia complicates 0.78e2.7 per 1000 pregnancies,
putting both gravida and fetus at increased risks. Compared
with pneumonia in a non-pregnant adult, the gravida faces
an increased risk of bacteremia, empyema, need for
mechanical ventilation and other less common complica-
tions. The main risks for the fetus are preterm labor and
22 S. Nir et al.preterm birth with low birth weight and subsequent asso-
ciated infant morbidity and mortality.1 Streptococcus
pneumoniae is the most common pathogen implicated in
community acquired pneumonia during pregnancy.2
Streptokinase is a fibrinolytic agent used for a variety of
conditions including the treatment of ‘‘complicated’’ par-
apneumonic pleural effusion. The efficacy of intrapleural
streptokinase, its benefit over tube thoracostomy alone,
and its potential for obviating the need for surgical inter-
vention has recently been put into question, although the
issue remains contraversial.3,4 To our knowledge this is the
first report of empyema treated with streptokinase in
advanced pregnancy.Case
A 24 year old, 33 week pregnant woman reported to the
emergency department with a three day history of fever of
38.5 C and weakness. One day prior to admission, she
developed worsening dyspnea, a non productive cough and
pain in the posterior right thorax. She was examined at
a community clinic where she received intra-venous fluids
and was offered antibiotic treatment, for suspected pneu-
monia, which she refused. She had no prior medical
conditions and had 3 previous uneventful pregnancies.
On admission the patient appeared pale, dyspneic and
was in considerable distress.
The respiratory rate was 45 breaths per minute with an
oxygen saturation of 95% while breathing room air. Use of
accessory muscles of respiration was noted. Her tempera-
ture was 37.3 C, heart rate 123 beats per minute and her
blood pressure 104/46 mmHg. Examination of the right
chest revealed diminished breath sounds, decreased vocal
fremitus and dullness to percussion. The abdomen was soft
with a prominent uterus appropriate for the gestational
week. Laboratory values showed mild hyponatremia of
132 mMol/l (135e145) and mild hypokalemia of 3.2 mMol/l
(3.5e5). Blood count showed leukocyte count of 6900/mm3
(4000e10,000), mild anemia with hemoglobin 10.7 gr/dL11e
15 and a platelet count of 186,000/mm3 (150,000e400,000)
Urinalysis, renal and liver functions were all within the
normal range. Chest x-ray showed a right lower lobe infil-
trate and suspected fluid. A chest sonogram done in the
emergency department showed right lower lobe consoli-
dation and no fluid. EKG showed sinus tachycardia without
signs of right ventricular strain. Fetal monitoring and
sonography on admission were reassuring.
The patient was hospitalized and started treatment with
intravenous Cefuroxime (750 mg TID) and oral Roxy-
thromycin (150 mg BID). Oral Tramadol HCl and Dipyrone
were administered for pleuritic pain. The status of the
fetus was monitored daily by an obstetrician and remained
reassuring. On the day after admission, the patient expe-
rienced subjective improvement but findings on physical
examination and chest radiography were compatible with
accumulating fluid in the right thorax (Fig. 1A). Oxygen
saturation decreased to 93% on room air. Repeat chest
sonogram showed pleural fluid and pleural aspiration was
used to drain 60 ml of frank pus, with a leukocyte count of
50,000/mm3 with 97% neutrophils A thoracostomy tube was
inserted and an additional 800 ml of purulent fluid weredrained (Fig. 1B). Due to the impression of residual fluid on
physical examination and repeat chest radiography and the
lack of additional drainage from the initial thoracostomy
tube, a second tube was inserted. On hospital day 3 blood
cultures grew S. pneumoniae, and antibiotic treatment was
switched to intravenous penicillin (4 million units every
6 h). However, the patient failed to show evidence of
clinical improvement with persistent dyspnea and low
grade fever. While there was no leukocytosis, the platelet
count continued to increase to a maximal value of 635,000/
mm3. Physical examination and radiographic studies
showed a significant amount of residual loculated fluid in
the right hemi-thorax (Fig. 1C). Following pulmonary and
thoracic surgical consultation, it was decided not to
perform surgical decortication at that time, and on hospital
day 7, treatment with streptokinase was initiated (250,000
units every 8 h administered through the thoracostomy
tube, total 9 doses over 72 h). Following the administration
of streptokinase a notable increase in the amount of fluid
drained was observed and the patient reported improve-
ment in her well being. Chest x-ray showed improvement
from the previous radiographs with smaller amounts of
fluid. The patient improved continuously and on hospital
day 13 the chest tubes were removed. A repeat chest
radiograph 24 h later did not show re-accumulation of fluid.
On hospital day 14, the patient was discharged with
treatment of oral penicillin (500 mg every 6 h) for an
additional 14 days. Chest x-ray done on the day of discharge
showed marked improvement (Fig. 1D).
The patient carried her pregnancy to term and went into
spontaneous labor after 39 weeks and 5 days of gestation. A
healthy female infant was delivered vaginally, weighing
3100 g with Apgar scores of 9 and 10 at 1 and 5 min
respectively.
A follow up chest x-ray done 5 months after her
discharge showed minimal residual pleural thickening in the
right costophrenic angle (Fig. 1E).Discussion
When caring for the acutely ill gravida, the clinician is
challenged by increased risks of morbidity and mortality to
the patient together with the need to minimize risk to the
fetus. Applying the ethical axiom that the gravida’s treat-
ment must not be compromised by obstetric considerations
may be challenging to apply in light of the patient’s wishes
and the different views of the treating physicians.
Pneumonia during pregnancy poses significantly
increased risks to both gravida and fetus. Although its
incidence appears to vary due to demographic and epide-
miologic trends2 pneumonia during pregnancy has been
cited as the chief non-obstetric infectious cause of death.5
The gravida’s condition may be complicated by bacteremia
in up to 16% of the cases, empyema in 8% and an increased
rate of mechanical ventilation.1 The fetus is faced with an
increased risk of placental abruption,6 preterm birth, low
birth weight and subsequent morbidity and mortality.1
Although recent studies suggest that community acquired
pneumonia in a young and otherwise healthy gravida is
generally well tolerated by both mother and fetus,7 the
risks mentioned above should not be overlooked.
Figure 1 A - Chest radiograph prior to tube thoracostomy insertion (day 1); B - Chest radiograph after tube thoracostomy
insertion (day 3); C - Loculated fluid after tube thoracostomy insertion (day 4); D - Chest radiograph prior to discharge (day 14);
E - Chest radiograph performed 5 months after discharge.
Streptokinase for empyema thoracis during advanced pregnancy 23The use of intrapleural streptokinase, a potent plas-
minogen activator, is a therapeutic option for the treat-
ment of loculated empyema. Its role, benefit and
advantages over sole tube thoracostomy3,4,8,9 and surgical
interventions such as open decortication or VATS*10 has
been widely debated. The study of Maskell et al.3 ques-
tion the place of intrapleural fibrinolytics as recom-
mended in earlier treatment guidelines.11e13 A subsequent
prospective randomized study found that this treatment is
of benefit.4 Due to the relatively small number of
randomized control trials the efficacy of intrapleural
streptokinase remains controversial. Of special relevance
in this case are findings that the results of surgical salvage
interventions are not compromised by a prior attempt of
thoracostomy and fibrinolytics10 and that prognosis is not
affected when decortication is delayed.14 Nevertheless, inthe midst of controversy there seems to be consensus
surrounding the need to consider selected subgroups of
patients (case-specific considerations) in decisions
regarding potential efficacy of intrapleural fibrinolytic
therapy.3,4,8
Successful intravascular use of streptokinase during
pregnancy for venous thromboembolism has been docu-
mented without fetal teratogenicity, obstetric complica-
tions or adverse effects.15,16 There has been one report of
a 1st trimester spontaneous miscarriage.15 A study of the
systemic fibrinolytic effect of intrapleural streptokinase
showed no significant change in systemic coagulation
indices and status following the administration of intra-
pleural streptokinase.17 The relatively short half life of
streptokinase is another advantage in the setting of the
pregnant patient and the need to avoid systemic effects.18
24 S. Nir et al.Our patient was managed in line with the treatment
algorithm proposed by the British Thoracic Society.11 The
need for expedient drainage was evident after thoracent-
esis yielded frank pus, a category 4 risk for poor outcome as
classified by ACCP** consensus.12 In this case, the use of
intrapleural streptokinase as an adjunct to tube thor-
acostomy and antibiotics was followed by a rapid resolution
of the empyema and clinical improvement. Surgical inter-
vention in the pregnant patient was thus avoided. We
therefore conclude that intrapleural streptokinase can be
used safely and effectively for the management of
empyema thoracis during pregnancy.
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